Clinical Trials Support Core The Clinical Trials Support Core (CTSC) is a shared resource available to all members of the HCCC. It is designed to facilitate execution of high quality clinical cancer investigation including both interventional and correlative science studies. The CTSC enhances interaction among HCCC members and provides for easy assembly of multi-departmental teams needed for collaboration on innovative protocols. The CTSC is composed of dedicated staff with expertise in protocol management and study coordination. Administratively, the Director of the CTSC works closely with the Assistant Director for Clinical Services, and reports to the Associate Director for Clinical and Translational Research. The CTSC provides investigators with appropriate routing of protocols through the various internal regulatory committees including the HCCC Protocol Review and Monitoring Committee, assists the investigator in protocol modifications and reporting of adverse events for ongoing clinical studies, and supplies staff with expertise in data management. The CTSC also provides support for translational research by assisting in the procurement of blood and other not surgical tissues for investigators. It participates in posting protocol lists and supporting internal communication regarding ongoing studies, as well as statistical reporting on accrual. A chargeback system is used to compensate the CTSC for support of most clinical trials run through the CTSC. The core also supports innovative, early phase clinical trials for which there is no other source of support.

Public Health Relevance

The Clinical Trials Support Core provides a centralized resource for investigators interested in clinical and translational cancer research. It is a vital shared resource if we are to translate basic science advances in cancer to the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-12
Application #
8381329
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$140,553
Indirect Cost
$32,874
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Mahauad-Fernandez, Wadie D; Naushad, Wasifa; Panzner, Tyler D et al. (2018) BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells. Sci Rep 8:17608
Lodge, Martin A; Leal, Jeffrey P; Rahmim, Arman et al. (2018) Measuring PET Spatial Resolution Using a Cylinder Phantom Positioned at an Oblique Angle. J Nucl Med 59:1768-1775
Swami, Umang; Ma, Deqin; Zhang, Jun (2018) Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. J Thorac Oncol 13:e129-e130
Heer, Collin D; Davis, Andrew B; Riffe, David B et al. (2018) Superoxide Dismutase Mimetic GC4419 Enhances the Oxidation of Pharmacological Ascorbate and Its Anticancer Effects in an H?O?-Dependent Manner. Antioxidants (Basel) 7:
Kondratick, Christine M; Litman, Jacob M; Shaffer, Kurt V et al. (2018) Crystal structures of PCNA mutant proteins defective in gene silencing suggest a novel interaction site on the front face of the PCNA ring. PLoS One 13:e0193333
Panel, Nicolas; Villa, Francesco; Fuentes, Ernesto J et al. (2018) Accurate PDZ/Peptide Binding Specificity with Additive and Polarizable Free Energy Simulations. Biophys J 114:1091-1102
Field, R William (2018) Radon: A Leading Environmental Cause of Lung Cancer. Am Fam Physician 98:280-282
Morrison, Emma A; Bowerman, Samuel; Sylvers, Kelli L et al. (2018) The conformation of the histone H3 tail inhibits association of the BPTF PHD finger with the nucleosome. Elife 7:
Liu, Yiwei; Dong, Zhengwei; Jiang, Tao et al. (2018) Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. Clin Lung Cancer 19:e421-e430
Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428

Showing the most recent 10 out of 1080 publications